AMSTERDAM and NEW YORK, Nov. 13, 2017 /PRNewswire/ -- Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, today announced that it will be showcasing its integrated vascular solutions comprising interventional X-ray systems, diagnostic and therapeutic devices, planning and navigation software and services at the 2017 VEITHsymposium (VEITH) in New York, New York (November 14 - 18, 2017). At the symposium, Philips will launch PVDandMe.com, a new patient education website providing resources on peripheral vascular disease (PVD) to help patients improve their quality of life.

One in every 20 Americans over the age of 50 has peripheral artery disease (PAD), a common peripheral vascular disease. If left untreated, PAD can become a serious condition linked to severe complications and an increased risk of a heart attack and stroke [1]. Since peripheral vascular disease often has few symptoms, the need for understanding of the condition and integrated solutions offering personalized care is extremely critical. Philips' new patient website provides information about common peripheral vascular disease conditions, signs, symptoms, causes and risk factors. Philips also has launched a complementary PVD site for healthcare providers, Philips.com/PVDresources, with tools to help clinicians establish an office-based laboratory, improving practice workflow and educating colleagues.

"The new Philips unbranded, patient-focused PVD website is a rich resource to aid patients with peripheral vascular disease in understanding their condition to seek treatment to improve their quality of life," said Dr. Raghu Kolluri, MS, MD, RVT, System Medical Director of Vascular Medicine at OhioHealth. "By offering extensive information from treatment options to the physician locator tool, Philips is helping patients better understand their diagnosis and seek appropriate treatment."
At VEITH, Philips will showcase its leading portfolio of interventional imaging systems, devices, software, and services. With its recent acquisition of Spectranetics in August 2017, Philips' expanded range of therapy devices for peripheral vascular disease at this year's symposium will include:

Azurion is the next generation image-guided therapy platform, which enables clinicians to easily and confidently perform a range of routine and complex procedures, helping them to optimize interventional lab performance and provide superior care.
Stellarex drug-coated balloon delivers top-tier clinical results for common to complex patients. As the only commercially available drug-coated balloon with two reported randomized controlled trials, Stellarex has demonstrated durability with consistently high patency rates in a wide range of patients.

Health IT Homepage